Previous Close | 5.63 |
Open | 5.69 |
Bid | 5.74 x 200 |
Ask | 5.79 x 100 |
Day's Range | 5.59 - 5.76 |
52 Week Range | 3.80 - 12.31 |
Volume | |
Avg. Volume | 692,025 |
Market Cap | 753.546M |
Beta (5Y Monthly) | 1.37 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.09 |
Earnings Date | May 06, 2024 - May 10, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 10.00 |
The average brokerage recommendation (ABR) for Cytek Biosciences (CTKB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
The heavy selling pressure might have exhausted for Cytek Biosciences (CTKB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The consensus price target hints at a 47.6% upside potential for Cytek Biosciences (CTKB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.